7DZW

Apo spike protein from SARS-CoV2

7DZW の概要

• エントリーDOI: 10.2210/pdb7dzw/pdb
• EMDBエントリー: 30915
• 分子名称: Spike glycoprotein (1 entity in total)
• 機能のキーワード: sars-cov2, spike protein, viral protein
• 由来する生物種: Severe acute respiratory syndrome coronavirus 2 (2019-nCoV, SARS-CoV-2)
• タンパク質・核酸の鎖数: 3
• 化学式量合計: 415160.34

構造登録者

Liu, Y.,Soh, W.T.,Li, S.,Kishikawa, J.,Hirose, M.,Kato, T.,Standley, D.,Okada, M.,Arase, H. (登録日: 2021-01-26, 公開日: 2021-06-02, 最終更新日: 2024-03-27)

主引用文献

Liu, Y.,Soh, W.T.,Kishikawa, J.I.,Hirose, M.,Nakayama, E.E.,Li, S.,Sasai, M.,Suzuki, T.,Tada, A.,Arakawa, A.,Matsuoka, S.,Akamatsu, K.,Matsuda, M.,Ono, C.,Torii, S.,Kishida, K.,Jin, H.,Nakai, W.,Arase, N.,Nakagawa, A.,Matsumoto, M.,Nakazaki, Y.,Shindo, Y.,Kohyama, M.,Tomii, K.,Ohmura, K.,Ohshima, S.,Okamoto, T.,Yamamoto, M.,Nakagami, H.,Matsuura, Y.,Nakagawa, A.,Kato, T.,Okada, M.,Standley, D.M.,Shioda, T.,Arase, H.
An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies.
Cell, 184:3452-3466.e18, 2021

PubMed Abstract: Antibodies against the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein prevent SARS-CoV-2 infection. However, the effects of antibodies against other spike protein domains are largely unknown. Here, we screened a series of anti-spike monoclonal antibodies from coronavirus disease 2019 (COVID-19) patients and found that some of antibodies against the N-terminal domain (NTD) induced the open conformation of RBD and thus enhanced the binding capacity of the spike protein to ACE2 and infectivity of SARS-CoV-2. Mutational analysis revealed that all of the infectivity-enhancing antibodies recognized a specific site on the NTD. Structural analysis demonstrated that all infectivity-enhancing antibodies bound to NTD in a similar manner. The antibodies against this infectivity-enhancing site were detected at high levels in severe patients. Moreover, we identified antibodies against the infectivity-enhancing site in uninfected donors, albeit at a lower frequency. These findings demonstrate that not only neutralizing antibodies but also enhancing antibodies are produced during SARS-CoV-2 infection.

PubMed: 34139176
DOI: 10.1016/j.cell.2021.05.032

実験手法

ELECTRON MICROSCOPY (3.45 Å)